- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03165838
Effectiveness of Shortened Time Interval to Postpartum Visit in Improving Postpartum Attendance
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Postpartum care is an essential component of women's reproductive health. During this time, the health care provider and the new mother review the previous pregnancy course, assess the mother's wellbeing, and establish treatment plans for any ongoing problems. Prospective guidance is given for both the mother and the baby in areas such as breastfeeding, nutrition, depression screening, and perineal/vulvar care. However, one of the most important goals of the postpartum visit is to discuss the new mother's desire for future pregnancies and the interval she wishes before another pregnancy. Inadequate reproductive health planning may result in unintended or rapid repeat of pregnancy (RROP), clinically defined as a second pregnancy within 24 months of the end of a previous pregnancy. A short inter-pregnancy interval is a risk factor for poor pregnancy outcomes including stillbirth, early neonatal death, extreme preterm births, and babies born small for gestational age. Compared to women who conceived 18-23 months after a previous birth, women conceiving less than five months after a previous birth had increased third trimester bleeding, uterine infection, premature rupture of membranes, and maternal death.Central to these outcomes is the rate of postpartum contraception use.
In fact, research shows an association between a postpartum visit and use of a reliable contraceptive method after pregnancy.
The optimal time for postpartum visit may be 3-4 weeks post-delivery rather than 6-8 weeks post-delivery with regard to visit attendance and proactive management of reproductive health, including contraception and time intervals between pregnancies. The timing of the postpartum visits are also linked to economic outcomes and healthcare utilization; postpartum care that results in decreased RROP and unintended pregnancies will likely decrease healthcare costs associated with the adverse consequences of inadequate reproductive health planning. Despite the obvious potential benefits of a decreased interval between delivery and the postpartum visit, to date, there have been no studies to systematically compare the impact of postpartum visit timing on visit attendance, contraception use and, subsequently, RROP.
This study is designed to investigate the effect of reduced time interval to postpartum visit on postpartum visit attendance rate, contraceptive use, and RROP. Additionally, the study will assess the impact of the two visit schedules on these outcomes by race, providing critical information about high risk populations. Finally, this research will assess the cost effectiveness of the shortened postpartum visit schedule relative to the standard of care. In order to account for potential bias in increased attendance rate due to intervention effect, compensation and other factors, this study will also compare the effectiveness of shortened time interval to postpartum visit on postpartum attendance rate and contraceptive use to a historic cohort.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- at least 18 years of age
- delivered vaginally a healthy, full-term (at least 37 weeks gestation) baby
- received prenatal care services at the VCUMCV OB clinic
- speak English
- provide informed consent for study participation.
Exclusion Criteria:
- cognitive impairment, psychiatric instability, or language barriers that limit their ability to provide informed consent
- surgically sterilized
- have complicated deliveries that require extended hospital stays
- need early follow-up to monitor their conditions
- any problems with infants such as preterm birth, admission to the Neonatal Intensive Care Unit (NICU), congenital malformations or respiratory problems that would require frequent clinic visits or prolonged hospital admissions for the infants.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Postpartum Visit 3-4 Weeks
Participants will have postpartum visit scheduled 3-4 weeks after birth
|
This visit will be the same as the standard of care postpartum visit, but it will be scheduled earlier.
|
|
Experimental: Postpartum Visit 6-8 Weeks
Participants will have postpartum visit scheduled 6-8 weeks after birth
|
This standard of care postpartum visit will be scheduled for the standard time interval.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Postpartum Clinic Attendance
Zeitfenster: assessed at 12 weeks postpartum
|
To compare the effectiveness of 3-4 week and 6-8 week intervals to postpartum visit on improving the rate of postpartum visit attendance.
The investigators hypothesize that study participants with postpartum visits scheduled 3-4 weeks after delivery will be more likely to attend visits than study participants scheduled for visits 6-8 weeks after delivery.
|
assessed at 12 weeks postpartum
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Contraception Use
Zeitfenster: Assessed at 3, 6, 9, 12, & 18 month follow-ups
|
Compare the effectiveness of 3-4 week and 6-8 week intervals to postpartum visit on consistent contraceptive use
|
Assessed at 3, 6, 9, 12, & 18 month follow-ups
|
|
Rapid Repeat Pregnancy
Zeitfenster: Assessed at 3, 6, 9, 12, & 18 month follow-ups
|
Compare the effectiveness of 3-4 week and 6-8 week intervals to postpartum visit on repeat pregnancy
|
Assessed at 3, 6, 9, 12, & 18 month follow-ups
|
|
Cost effectiveness
Zeitfenster: 18 month postpartum
|
Compare overall cost of postpartum care
|
18 month postpartum
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Racial Differences
Zeitfenster: baseline, postpartum, 3, 6, 9, 12, & 18 month follow-ups
|
Compare the effectiveness of 3-4 week and 6-8 week intervals to postpartum visit on reducing racial differences in postpartum visit attendance rates and contraceptive use.
Specifically, the study team hypothesizes that the difference in postpartum visit attendance and consistent contraceptive use rates between AA and CA study participants will be lower among study participants with postpartum visits scheduled 3-4 weeks after delivery compared to study participants scheduled for visits 6-8 weeks after delivery.
|
baseline, postpartum, 3, 6, 9, 12, & 18 month follow-ups
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Saba W Masho, Virginia Commonwealth University
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Yonemoto N, Nagai S, Mori R. Schedules for home visits in the early postpartum period. Cochrane Database Syst Rev. 2021 Jul 21;7(7):CD009326. doi: 10.1002/14651858.CD009326.pub4.
- Masho SW, Ihongbe TO, Wan W, Graves WC, Karjane N, Dillon P, Bazzoli G, McGee E. Effectiveness of shortened time interval to postpartum visit in improving postpartum attendance: Design and rationale for a randomized controlled trial. Contemp Clin Trials. 2019 Jun;81:40-43. doi: 10.1016/j.cct.2019.04.012. Epub 2019 Apr 18.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- HM20000032
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Schwangerschaft bezogen
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
China National Center for Cardiovascular DiseasesChinese Academy of Medical Sciences, Fuwai HospitalAktiv, nicht rekrutierendLungenentzündung | Sepsis | Infektion | Driveline Heart-assisted Device Related InfectionChina
-
Hospices Civils de LyonAbgeschlossenNeuromyelitis-Optica-Spektrum-Erkrankungen | Neuromyelitis optica Spectrum Related DisordersFrankreich
-
Cure CMDRekrutierungEmery-Dreifuss-Muskeldystrophie | Angeborenes myasthenisches Syndrom | Gliedergürtel-Muskeldystrophie | Angeborene Muskeldystrophie mit ITGA7 (Integrin Alpha-7)-Mangel | Alpha-Dystroglykanopathie (angeborene Muskeldystrophie und abnormale Glykosylierung von Dystroglykan bei schwerer Epilepsie) und andere BedingungenVereinigte Staaten
Klinische Studien zur Postpartum Visit 3-4 Weeks
-
Jeffrey A. Cohen, MDJacobus PharmaceuticalBeendetMuskelschwächeVereinigte Staaten
-
University of DundeeZurückgezogen
-
Pharma Holdings ASCTC Clinical Trial Consultants ABAbgeschlossenNasale Entkolonialisierung von Staphylococcus AureusSchweden
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Beendet
-
Seoul National University HospitalUnbekannt
-
Merz Pharmaceuticals GmbHAbgeschlossenKorrektur von Gesichtsfalten/-falten | Verbesserung des GesichtsvolumensDeutschland
-
IpsenAktiv, nicht rekrutierendPrimäre biliäre CholangitisJapan
-
AccSalus Biosciences, Inc.Noch keine RekrutierungMelanom | Nierenzellkarzinom | Hepatozelluläres Karzinom | Adenokarzinom des Magens | Fortgeschrittener solider Tumor | Adenokarzinom des gastroösophagealen Überganges | Gallenblasenkrebs | Schilddrüsenkarzinom, medullär | Primäres differenziertes Schilddrüsenkarzinom
-
REDNVIA Co., Ltd.SuspendiertVerkalkte AortenklappenerkrankungVereinigte Staaten, Kanada
-
IpsenRekrutierungPrimär sklerosierende CholangitisVereinigte Staaten